SynBioBeta Speaker
Eric Kauderer-Abrams
Anthropic
Head of Biology & Life Sciences
Eric Kauderer-Abrams leads is the Head of Life Sciences at Anthropic, where he runs the company's effort to make Claude useful for drug development, basic research, and more. He launched Claude for Life Sciences, working with partners on applications spanning drug discovery, clinical trials, and regulatory work.Before Anthropic, he co-founded and served as CEO and CTO of Detect, a molecular diagnostics company that brought an FDA-authorized at-home COVID test to market, and earlier co-founded companies at the intersection of AI and MedTech. He did graduate research in AI and neuroscience at Stanford, following undergraduate training in mathematics and physics at Penn.
Sessions Featuring
Eric
This Year
•
-
AIxBIO
AI + Biopharma Luncheon
The AI + Biopharma Luncheon at SynBioBeta 2026 brings together innovators working at the intersection of artificial intelligence and life sciences. This gathering offers a chance for founders, researchers, investors, and industry leaders to connect over lunch while exploring how AI is accelerating drug discovery, transforming R&D workflows, and reshaping the future of biopharma. The luncheon will also feature a panel discussion with Vivek Ardash, CEO of Mithrl, and Eric Kauderer-Abrams, Life Sciences at Anthropic, offering perspectives on how frontier AI models, scientific reasoning systems, and new computational tools are beginning to change the way biopharma teams generate insights, design experiments, and move from discovery to development.
•
-
AIxBIO
AI + Biopharma Luncheon
The AI + Biopharma Luncheon at SynBioBeta 2026 brings together innovators working at the intersection of artificial intelligence and life sciences. This gathering offers a chance for founders, researchers, investors, and industry leaders to connect over lunch while exploring how AI is accelerating drug discovery, transforming R&D workflows, and reshaping the future of biopharma. The luncheon will also feature a panel discussion with Vivek Ardash, CEO of Mithrl, and Eric Kauderer-Abrams, Life Sciences at Anthropic, offering perspectives on how frontier AI models, scientific reasoning systems, and new computational tools are beginning to change the way biopharma teams generate insights, design experiments, and move from discovery to development.
•
-
Human Health
From Models to Medicines: AI Meets the Next Generation of Drug Discovery
As AI begins to move from prediction to real-world impact, its convergence with biology is opening new frontiers in drug discovery. In this conversation, Eric Kauderer-Abrams, Head of Biology & Life Sciences at Anthropic, and Marc Tessier-Lavigne, CEO of Xaira Therapeutics explore how foundation models, large-scale biological data, and experimental science are coming together to reshape how we understand and treat disease. From decoding complex biological systems to guiding therapeutic design, they’ll discuss what it takes to translate AI capabilities into clinically meaningful outcomes, and where the biggest opportunities and limitations still lie.
•
-
Human Health
From Models to Medicines: AI Meets the Next Generation of Drug Discovery
As AI begins to move from prediction to real-world impact, its convergence with biology is opening new frontiers in drug discovery. In this conversation, Eric Kauderer-Abrams, Head of Biology & Life Sciences at Anthropic, and Marc Tessier-Lavigne, CEO of Xaira Therapeutics explore how foundation models, large-scale biological data, and experimental science are coming together to reshape how we understand and treat disease. From decoding complex biological systems to guiding therapeutic design, they’ll discuss what it takes to translate AI capabilities into clinically meaningful outcomes, and where the biggest opportunities and limitations still lie.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
